| Nov 12 |
Indaptus Therapeutics GAAP EPS of -$0.32
|
| Nov 12 |
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 11 |
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
|
| Nov 7 |
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
|
| Oct 15 |
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data
|
| Oct 10 |
Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy
|
| Sep 13 |
Indaptus Therapeutics files to sell 1.64M shares of common stock for holders
|
| Sep 5 |
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
|
| Sep 3 |
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 11 |
Insider Buyers Lose US$41k As Indaptus Therapeutics Sheds US$1.2m
|
